PathMaker Neurosystems Sponsored by NIH to Participate in the Innovation Zone at the 2019 BIO International Convention.
Boston, Massachusetts, & Paris, France, May 31, 2019 – PathMaker Neurosystems Inc. (“PathMaker”), a clinical-stage bioelectronic medicine company developing non-invasive systems for the treatment of patients with neuromotor disorders, has been selected by NIH to participate in the Innovation Zone at this year’s BIO International Convention.
The Innovation Zone is a partnership between the Biotechnology Innovation Organization and the National Institutes of Health to feature Small Business Innovation Research (SBIR) funded early-stage biotech companies to showcase their cutting-edge technologies, and facilitate the formation of long-term partnerships. PathMaker Neurosystems is the recipient of a $5M award through the CREATE Devices program that provides a collaborative partnership with the National Institute of Neurological Disorders and Stroke (NINDS).
“I am looking forward to discussing the development of MyoRegulator®, our investigational, first-in-class, neuromodulation device which provides simultaneous non-invasive stimulation at spinal and peripheral sites for the treatment of patients suffering from spasticity,” said Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer of PathMaker. “Our recently completed human clinical trial to evaluate the performance and safety of the MyoRegulator device in active versus sham treated patients represents the first trial assessing the use of this kind of device in spasticity.”
While visiting BIO International, plan to stop by the BIO Innovation Zone in Booth 4270 across from the Start-Up Stadium.
About PathMaker Neurosystems Inc.
PathMaker Neurosystems is a clinical-stage bioelectronic medicine company developing breakthrough non-invasive systems for the treatment of patients with chronic neuromotor conditions. With offices in Boston (U.S.) and Paris (France), we are collaborating with world-class institutions to rapidly bring to market disruptive products for treating spasticity, paralysis and muscle weakness. More than 48 million patients in the U.S., Europe and China suffer disabilities due to stroke, cerebral palsy, multiple sclerosis, spinal cord injury, traumatic brain injury, Parkinson’s disease and other neurological disorders. At PathMaker, we are opening up a new era of non-invasive neurotherapy for patients suffering from chronic neuromotor conditions. For more information, please visit the company website at www.pmneuro.com.
Source: PathMaker Neurosystems Inc.
Lisa DeScenza, Assistant Vice President, Integrated Communications